Abstract: Aspects of the invention relate to topical and ocular formulations of spherical nucleic acids (SNA), as well as methods of use thereof and compositions thereof.
Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.
Type:
Grant
Filed:
October 6, 2015
Date of Patent:
February 19, 2019
Assignee:
Exicure, Inc.
Inventors:
Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
Type:
Grant
Filed:
December 3, 2014
Date of Patent:
January 22, 2019
Assignees:
NORTHWESTERN UNIVERSITY, EXICURE, INC.
Inventors:
Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as a GGG. Related methods are also described.
Abstract: The invention relates to spherical nucleic acids for the delivery of lipid nucleic acid particles. The lipid nucleic acid particles containing one or more therapeutic agents are coated with an oligonucleotide shell to enhance delivery.
Abstract: Immunoregulatory spherical nucleic acids (irSNAs) composed of a lipid containing core and an inert Nucleic non-TLR antagonistic oligonucleotide shell are provided. Acid Shell These it-SNAs are useful for modulating an immune response.
Type:
Application
Filed:
February 18, 2016
Publication date:
February 15, 2018
Applicant:
Exicure, Inc.
Inventors:
Sergei Gryaznov, Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Tiffany L. Halo, Richard Kang, Subbarao Nallagatla, Clayton Rische, Sagar Anantatatmula
Abstract: Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of G-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of G-quadruplex stabilizing domains linked to the G-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as Toll-like receptors; for inhibiting DNA or RNA expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases.
Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
Type:
Application
Filed:
June 4, 2015
Publication date:
June 8, 2017
Applicant:
Exicure, Inc.
Inventors:
Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
Abstract: Aspects of the invention relate to nanoscale constructs and related methods and compositions thereof. The compositions of the invention are useful for treating disorders that are sensitive to levels of immune cell activation, such as autoimmune disease or other inflammation based disease or disorder.
Type:
Application
Filed:
July 25, 2014
Publication date:
July 7, 2016
Applicant:
Exicure, Inc
Inventors:
Sergei Gryaznov, Christopher C. Mader, Tiffany L. Halo, Aleksandar Filip Radovic-Moreno, Clayton Rische, Sagar Anantatmula